S2Medical Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Petter Sivlér

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	11.3yrs
CEO ownership	0.001%
Management average tenure	no data
Board average tenure	2.4yrs

Recent management updates

Recent updates

CEO

Petter Sivlér (38 yo)

11.3yrs

Tenure

Mr. Petter Sivlér Co-Founded S2Medical AB (publ) and has been its Chief Executive Officer from 2013.

Board Members

Name	Position	Tenure	Compensation	Ownership
Mårten Skog	Co-Founder	11.3yrs	no data	no data
Fredrik Skog	Chair of the Board	2.4yrs	no data	0.0098% SEK 2.3k
Miles Wright	Director	2.4yrs	no data	no data
Chadi Asaad	Director	2.4yrs	no data	no data
Patrick Sheehan	Director	2.4yrs	no data	no data

2.4yrs

Average Tenure

Experienced Board: S2M's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

S2Medical Management

Management criteria checks 0/4

Key information

Recent management updates

No independent directors

S2Medical AB (Publ) Announces Appointment of Ingvild Thiry as Chief Financial Officer

No independent directors

Recent updates

Full year 2023 earnings released: kr0.082 loss per share (vs kr1.24 loss in FY 2022)

New major risk - Shareholder dilution

Third quarter 2023 earnings released

Second quarter 2023 earnings released

S2Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

New major risk - Shareholder dilution

First quarter 2023 earnings released

Full year 2022 earnings released: kr1.15 loss per share (vs kr1.35 loss in FY 2021)

S2Medical AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

S2Medical AB (publ) Announces the Positive Outcome of Antimicrobial Peptides Tests Against the Multi Resistant Bacteria

No independent directors

Third quarter 2022 earnings released

EPO Announces Intention to Approve Patenting of S2Medical AB's AMP Technology

S2Medical AB Announces Positive outcome from evaluation of Epiprotect in Saudi Arabia

S2Medical AB (publ) Updates Instagraft-Patent Approval in Israel

S2Medical AB (publ) Receives the Response from the European Patent Office That They Intend to Grant Patent Protection for the Company's Instagraft Technology Within Around Forty European Countries

S2Medical AB (Publ) Announces Appointment of Ingvild Thiry as Chief Financial Officer

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues in line with analyst expectations

Second quarter 2021 earnings released

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.33 loss per share (vs kr1.63 loss in FY 2019)

New 90-day low: kr7.50

New 90-day low: kr7.98

S2Medical AB (publ) (OM:S2M) entered into an agreement to acquire Curenc AB.

New 90-day high: kr9.69

Earnings released

CEO

Tenure

Board Members

Average Tenure